Sunday 11 October 2026 Export all SNY data to Excel Powerpack

Sanofi

SNY Healthcare Drug Manufacturers General

Sanofi’s revenue for fiscal 2025 (year ended December 2025) was $52.9 billion, up 10.3% from fiscal 2024. In the quarter to June 2026, revenue grew 17.4%, EPS fell 90.8%, free cash flow fell 45.1% and total debt rose 8.23%, each against the same quarter a year earlier. Dividend growth for three consecutive years.

40.07 0.16 −0.40%
Market cap
$95.9B
P/E
21.0×
Fwd P/E
—
Dividend yield
6.05%
F-score
7/9
Altman Z
2.50
Beneish M
−2.63
Dividend safety
58/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
6 — 7 —

+8 more TTM periods

ROE
5.87% 0.00% 10.94% 0.00%
ROA
3.21% 6.06% 6.16% 7.01%
ROIC
6.58% 6.12% 6.57% 6.17%
Return on Tangible Assets
40.46% 72.55% 61.72% 75.08%
Average Days of Receivables
68.60 3.75 68.81 4.53
Free Cash Flow per Share
6.08 0.00 7.62 0.00
Free Cash Flow
14,542.46 — 18,607.12 —
Capital Expenditures
(7,054.14) — (7,417.62) —
Other line items
Cash ROIC
12.82% 0.00% 16.79% 0.00%
Accounts Receivable Turnover
5.69 105.97 5.55 9.30
Accounts Payable Turnover
1.90 0.62 1.79 0.76
Inventory Turnover
1.30 0.61 1.36 0.64
Average Days of Payables
195.73 630.21 205.90 732.11
Days of Inventory on Hand
304.59 652.28 285.70 815.34
Tax Rate
(0.22) (0.17) (0.17) (0.18)
Research and Development Expense of Revenue
16.58% 16.43% 16.79% 18.12%
Selling, General and Administrative Expense of Revenue
20.11% 20.39% 20.43% 19.05%
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Interest Coverage
13.21 15.83 15.43 10.91
Operating CF/Net income
4.61 0.00 2.94 0.00
Depreciation/Fixed assets
1.30 0.00 1.22 0.00
Capex/Depreciation
(0.45) — (0.53) —
Revenue per Share
23.80 22.77 21.65 19.20
Operating CF per Share
9.02 0.00 10.66 0.00
Capex per Share
(2.95) 0.00 (3.04) 0.00
Capex to Sales
0.12 0.00 0.14 0.00

Fold the line items

Columns are period end dates